EQS-Adhoc: Viromed Medical AG will not acquire ActivCell Group AG and is focusing on another strategic option with greater added value

Viromed Medical AG will not acquire ActivCell Group AG and is focusing on another strategic option with greater added value

Pinneberg, 29 November 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) has terminated negotiations for the planned acquisition of all shares in ActivCell Group AG, Switzerland, and will not pursue this opportunity further.

On 17 September, Viromed had originally announced its intention to acquire 100% of ActivCell Group AG. The purchase price for this was to be in the mid-single-digit million euro range and was to be paid exclusively by granting new shares in the company, making partial use of the authorized capital 2022, in the context of a capital increase against contributions in kind, excluding shareholders' subscription rights.

In the course of further negotiations, Viromed's management board has come to the conclusion that the added value of the proposed transaction in relation to the purchase price does not meet the company's expectations. Therefore, the negotiations will not be continued.

Viromed Medical AG already has its own device, ViroCAP, which is by far the most advanced and innovative model in this field. The company has already made significant progress in the MDR 2a approval process with this device and is now focusing on bringing it to market on a broad scale.

Contact Viromed Medical AG

Uwe Perbandt CEO Flensburger Strasse 18 25421 Pinneberg Germany Email: kontakt@viromed-medical.de www.viromed-medical-ag.de